The stock of Editas Medicine Inc (NASDAQ:EDIT) registered a decrease of 0.67% in short interest. EDIT’s total short interest was 8.41 million shares in December as published by FINRA. Its down 0.67% from 8.46M shares, reported previously. With 744,800 shares average volume, it will take short sellers 11 days to cover their EDIT’s short positions.
The stock increased 1.58% or $0.48 during the last trading session, reaching $30.77. About 1.40M shares traded or 85.74% up from the average. Editas Medicine, Inc. (NASDAQ:EDIT) has declined 14.14% since December 4, 2018 and is downtrending. It has underperformed by 14.14% the S&P500.
Editas Medicine, Inc. operates as a genome editing company. The company has market cap of $1.58 billion. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. It currently has negative earnings. It is developing a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.
More notable recent Editas Medicine, Inc. (NASDAQ:EDIT) news were published by: Nasdaq.com which released: “Noteworthy Friday Option Activity: GS, CAG, SNPS – Nasdaq” on November 22, 2019, also Nasdaq.com with their article: “ETFs in Focus as US Homebuilder Sentiment Drops in November – Nasdaq” published on November 19, 2019, Nasdaq.com published: “THE REUTERS GRAPHIC-How Hong Kong’s keyboard warriors have besieged Wikipedia – Nasdaq” on November 28, 2019. More interesting news about Editas Medicine, Inc. (NASDAQ:EDIT) were released by: Nasdaq.com and their article: “Noteworthy ETF Outflows: XLY – Nasdaq” published on November 26, 2019 as well as Fool.com‘s news article titled: “Here’s Why Editas Medicine Jumped 45.3% in November – The Motley Fool” with publication date: December 04, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.